SLC16A1 and breast carcinoma: MCT- 1 serves as a negative prognostic indicator for aggressive breast cancer, as it facilitates IL- 6/IL- 6R/gp130 signaling-mediated epithelial‒mesenchymal transition (EMT) and the progression of TNBC [51].